Skip to main content

Science and Technology Committee examine regenerative medicine

13 October 2016

The Science and Technology Committee holds its second evidence session on regenerative medicine. This session focuses on commercialisation and transplantation stages of regenerative medicine and the challenges on clinical trials, ATMPs, regulation, market access and reimbursement and the impact on its adoption and use in the NHS.


Wednesday 19 October 2016, 1.45 pm, Committee Room 15, Palace of Westminster

At 1.45pm

  • Dr Ian Hudson, Chief Executive, Medicines and Healthcare products Regulatory Agency
  • Professor Paul Whiting, Member, MRC Regenerative Medicine Research Committee
  • Dr Sven Kili, Head of Gene Therapy Development, GSK
  • Michael Hunt, Chief Financial Officer, ReNeuron Group

At 2.45pm

  • Ian Trenholm, Chief Executive, NHS Blood and Transplant
  • Ian McCubbin, Medicines Manufacturing Industry Partnership and co-chair of the Advanced Therapy Manufacturing Taskforce
  • Keith Thompson, Chief Executive Officer, Cell and Gene Therapy Catapult
  • Dr Ruth McKernan, Chief Executive, Innovate UK 

Further information

Image: iStockphoto
Video: Parliamentary copyright